Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

99 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Formulation development of a live attenuated human rotavirus (RV3-BB) vaccine candidate for use in low- and middle-income countries.
Kumar P, Shukla RS, Patel A, Pullagurla SR, Bird C, Ogun O, Kumru OS, Hamidi A, Hoeksema F, Yallop C, Bines JE, Joshi SB, Volkin DB. Kumar P, et al. Among authors: ogun o. Hum Vaccin Immunother. 2021 Jul 3;17(7):2298-2310. doi: 10.1080/21645515.2021.1885279. Epub 2021 Apr 16. Hum Vaccin Immunother. 2021. PMID: 33861183 Free PMC article.
Modeling the long-term 2-8 °C stability profiles of a live, rotavirus vaccine candidate (RV3-BB) in various liquid formulations via extrapolations of real-time and accelerated stability data.
Pullagurla SR, Kumar P, Ogun O, Kumru OS, Hamidi A, Hoeksema F, Yallop C, Bines JE, Volkin DB, Joshi SB. Pullagurla SR, et al. Among authors: ogun o. Biologicals. 2022 Jan;75:21-28. doi: 10.1016/j.biologicals.2021.12.001. Epub 2021 Dec 17. Biologicals. 2022. PMID: 34924260 Free article.
Analytical and Preformulation Characterization Studies of Human Papillomavirus Virus-Like Particles to Enable Quadrivalent Multi-Dose Vaccine Formulation Development.
Jerajani K, Wan Y, Hickey JM, Kumru OS, Sharma N, Pullagurla SR, Ogun O, Mapari S, Whitaker N, Brendle S, Christensen ND, Batwal S, Mahedvi M, Rao H, Dogar V, Chandrasekharan R, Shaligram U, Joshi SB, Volkin DB. Jerajani K, et al. Among authors: ogun o. J Pharm Sci. 2022 Nov;111(11):2983-2997. doi: 10.1016/j.xphs.2022.07.019. Epub 2022 Jul 30. J Pharm Sci. 2022. PMID: 35914546 Free article.
Multi-Dose Formulation Development for a Quadrivalent Human Papillomavirus Virus-Like Particle-Based Vaccine: Part I - Screening of Preservative Combinations.
Jerajani K, Wan Y, Kumru OS, Pullagurla SR, Kumar P, Sharma N, Ogun O, Mapari S, Brendle S, Christensen ND, Batwal S, Mahedvi M, Rao H, Dogar V, Chandrasekharan R, Shaligram U, Joshi SB, Volkin DB. Jerajani K, et al. Among authors: ogun o. J Pharm Sci. 2023 Feb;112(2):446-457. doi: 10.1016/j.xphs.2022.09.001. Epub 2022 Sep 9. J Pharm Sci. 2023. PMID: 36096284 Free article.
Multi-dose Formulation Development for a Quadrivalent Human Papillomavirus Virus-Like Particle-Based Vaccine: Part II- Real-time and Accelerated Stability Studies.
Sharma N, Jerajani K, Wan Y, Kumru OS, Pullagurla SR, Ogun O, Mapari S, Brendle S, Christensen ND, Batwal S, Mahedvi M, Rao H, Dogar V, Chandrasekharan R, Shaligram U, Volkin DB, Joshi SB. Sharma N, et al. Among authors: ogun o. J Pharm Sci. 2023 Feb;112(2):458-470. doi: 10.1016/j.xphs.2022.11.021. Epub 2022 Dec 1. J Pharm Sci. 2023. PMID: 36462710 Free article.
Effectiveness of BNT162b2 BA.4/5 bivalent mRNA vaccine against a range of COVID-19 outcomes in a large health system in the USA: a test-negative case-control study.
Tartof SY, Slezak JM, Puzniak L, Hong V, Frankland TB, Ackerson BK, Xie F, Takhar H, Ogun OA, Simmons S, Zamparo JM, Valluri SR, Jodar L, McLaughlin JM. Tartof SY, et al. Among authors: ogun oa. Lancet Respir Med. 2023 Dec;11(12):1089-1100. doi: 10.1016/S2213-2600(23)00306-5. Epub 2023 Oct 25. Lancet Respir Med. 2023. PMID: 37898148
99 results